Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Quest Diagnostics, Inc shares valued at $968,625 were purchased by Plewman Patrick on Aug 06 ’25. At $175.00 per share, Plewman Patrick acquired 5,535 shares.
Also, KUPPUSAMY KARTHIK sold 8,269 shares, netting a total of over 1,384,231 in proceeds. Following the sale of shares at $167.40 each, the insider now holds 10,660 shares.
Before that, KUPPUSAMY KARTHIK had sold 2,210 shares from its account. In a trade valued at $375,700, the SVP, Clinical Solutions traded Quest Diagnostics, Inc shares for $170.00 each. Upon closing the transaction, the insider’s holdings decreased to 2,210 shares, worth approximately $1.46 million.
As published in their initiating research note from Redburn Atlantic on April 02, 2025, Quest Diagnostics, Inc [DGX] has been a Buy and the price target has been revised to $195. Analysts at Citigroup downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early March. As of January 06, 2025, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for DGX. Earlier on December 17, 2024, Morgan Stanley upgraded its rating. Their new recommendation was “an Overweight” for DGX stock which previously was a “an Equal-weight”.
Analyzing DGX Stock Performance
On last trading session, Quest Diagnostics, Inc [NYSE: DGX] plunged -0.16% to $173.0. The stock’s lowest price that day was $171.79, but it reached a high of $175.48 in the same session. During the last five days, there has been a surge of approximately 2.53%. Over the course of the year, Quest Diagnostics, Inc shares have jumped approximately 15.27%.
Is Quest Diagnostics, Inc subject to short interest?
Stocks of Quest Diagnostics, Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.94 million shares to 4.58 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 3.64 million shares. A jump of 20.45% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.84 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.84.
Which companies own the most shares of Quest Diagnostics, Inc (DGX)?
In terms of Quest Diagnostics, Inc share price expectations, FactSet research, analysts set an average price target of 190 in the next 12 months, up nearly 9.66% from the previous closing price of $173.27. Analysts anticipate Quest Diagnostics, Inc stock to reach 195 by 2025, with the lowest price target being 185. In spite of this, 10 analysts ranked Quest Diagnostics, Inc stock as Buy at the end of 2025. On December 10, 2024, Jefferies assigned a price target of “a Buy” to the stock and resumed coverage with a $185.
